Search for: ""Daubert v. Merrell Dow Pharmaceuticals, Inc." OR "509 U.S. 579""
Results 61 - 80
of 108
Sort by Relevance
|
Sort by Date
27 Dec 2012, 5:07 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 593-94 (1993) are relevant to the Court’s reliability determination under CRE 702, which is identical to FRE 702. [read post]
24 Dec 2012, 9:58 am
Merrell Dow Pharmaceuticals Inc., 509 U.S. 579 (1993), a case that has been superseded by subsequent cases and a revision to the operative statute, Rule 702. [read post]
20 Aug 2012, 11:04 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993)? [read post]
20 Aug 2012, 11:04 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993)? [read post]
19 Jul 2012, 4:07 pm
Evid. 702 2000 advisory commitee’s note; Daubert, 509 U.S. at 593, 113 S.Ct. 2786. [read post]
28 Jun 2012, 7:10 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993). [read post]
14 Jun 2012, 7:27 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 113 S.Ct. 2786, 125 L.Ed. 2d 469 (1993). [read post]
23 Apr 2012, 3:30 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), and Kumho Tire Co., Ltd. v. [read post]
18 Apr 2012, 1:14 pm
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993) provided a number of factors that typically 'bear on the inquiry'. [read post]
23 Mar 2012, 1:59 pm
Merrell Dow Pharmaceutical, Inc., 509 U.S. 579 (1993) and its progeny. [read post]
25 Jan 2012, 6:42 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 113 S.Ct. 2786 (1993), and discussed in Taylor v. [read post]
9 Nov 2011, 6:30 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993) and progeny. [read post]
25 Oct 2011, 9:05 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 595 (1993), that “[e]xpert evidence can be both powerful and quite misleading because of the difficulty in evaluating it. [read post]
24 Jun 2011, 1:24 pm
” Wal-Mart Stores, Inc. v. [read post]
21 Jun 2011, 5:00 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), applies to class certifications. [read post]
13 May 2011, 1:44 pm
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993). [read post]
22 Feb 2011, 7:27 pm
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), in analyzing the expert presentations relating to the Rule 23 requirements, Plaintiffs contend that the Ninth Circuit found this to be no abuse of discretion, and that it did not matter because the district court judge was "guided by Daubert," concluded that the expert opinions were "based on valid principles," and were "sufficiently probative"… [read post]
22 Feb 2011, 7:27 pm
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), in analyzing the expert presentations relating to the Rule 23 requirements, Plaintiffs contend that the Ninth Circuit found this to be no abuse of discretion, and that it did not matter because the district court judge was "guided by Daubert," concluded that the expert opinions were "based on valid principles," and were "sufficiently probative" of the Rule 23 requirements. [read post]
24 Aug 2010, 11:34 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), in which the Court instructed district courts to function as gatekeepers and permit only reliable and relevant expert testimony to be presented to the jury. [read post]
4 Aug 2010, 7:57 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993) established the test federal (and many state) judges currently use to determine the admissibility of expert testimony in trials and other proceedings. [read post]
